Mantovani F, Collavin L, Del Sal G (2019) Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26:199–212

Article  PubMed  Google Scholar 

Hall C, Muller PAJ (2019) The diverse functions of mutant 53, its family members and isoforms in cancer. Int J Mol Sci 20:6188

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blandino G, Di Agostino S (2018) New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res CR 37:30

Article  PubMed  Google Scholar 

Kennedy MC, Lowe SW. Mutant p53: it’s not all one and the same. Cell Death Differ. 2022;

Zhu G, Pan C, Bei J-X, Li B, Liang C, Xu Y et al (2020) Mutant p53 in cancer progression and targeted therapies. Front Oncol 10:595187

Article  PubMed  PubMed Central  Google Scholar 

Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA et al (2021) Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol Off J Am Soc Clin Oncol 39:1584–1594

Article  CAS  Google Scholar 

Hassin O, Oren M (2023) Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov 22:127–144

Article  CAS  PubMed  Google Scholar 

Shi Y, Jin J, Ji W, Guan X (2018) Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer 17:99

Article  PubMed  PubMed Central  Google Scholar 

Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582

Article  Google Scholar 

Chow LQM (2020) Head and Neck Cancer. N Engl J Med 382:60–72

Article  CAS  PubMed  Google Scholar 

Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10:191–202

Article  PubMed  Google Scholar 

Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S et al (2016) YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep 17:188–201

Article  PubMed  Google Scholar 

Cordani M, Oppici E, Dando I, Butturini E, Dalla Pozza E, Nadal-Serrano M et al (2016) Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol Oncol 10:1008–1029

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S et al (2017) The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep 18:1331–1351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E et al (2011) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle Georget Tex 10:4330–4340

Article  CAS  Google Scholar 

Zhang C, Ni C, Lu H (2022) Polo-like kinase 2: from principle to practice. Front Oncol 12:956225

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanan EJ, Fucini RV, Romanowski MJ, Elling RA, Lew W, Purkey HE et al (2008) Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett 18:5186–5189

Article  CAS  PubMed  Google Scholar 

Valenti F, Sacconi A, Ganci F, Grasso G, Strano S, Blandino G et al (2019) The miR-205-5p/BRCA1/RAD17 axis promotes genomic instability in head and neck squamous cell carcinomas. Cancers 11:1347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98-102

Article  CAS  PubMed  Google Scholar 

Bartha Á, Győrffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22:2622.

Tibor Fekete J, Győrffy B (2022) A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell lines. Comput Struct Biotechnol J 20:2885–2894

Article  CAS  PubMed  PubMed Central  Google Scholar 

Győrffy B (2023) Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience 45:1889–1898

Article  PubMed  PubMed Central  Google Scholar 

Vanderdys V, Allak A, Guessous F, Benamar M, Read PW, Jameson MJ et al (2018) The neddylation inhibitor pevonedistat (MLN4924) suppresses and radiosensitizes head and neck squamous carcinoma cells and tumors. Mol Cancer Ther 17:368–380

Article  CAS  PubMed  Google Scholar 

Fleisher B, Lezeau J, Werkman C, Jacobs B, Ait-Oudhia S (2021) In vitro to clinical translation of combinatorial effects of doxorubicin and abemaciclib in Rb-positive triple negative breast cancer: a systems-based pharmacokinetic/pharmacodynamic modeling approach. Breast Cancer Dove Med Press 13:87–105

CAS  PubMed  PubMed Central  Google Scholar 

Manna S, Holz MK (2016) Tamoxifen action in ER-negative breast cancer. Signal Transduct Insights 5:1–7

Article  Google Scholar 

Rozeboom AM, Pak DTS (2012) Identification and functional characterization of polo-like kinase 2 autoregulatory sites. Neuroscience 202:147–157

Article  CAS  PubMed  Google Scholar 

Vijayakumaran R, Tan KH, Miranda PJ, Haupt S, Haupt Y (2015) Regulation of mutant p53 protein expression. Front Oncol 5:284

Article  PubMed  PubMed Central  Google Scholar 

Yamamoto S, Iwakuma T (2018) Regulators of oncogenic mutant TP53 gain of function. Cancers 11:4

Article  PubMed  PubMed Central  Google Scholar 

Hanel W, Moll UM (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113:433–439

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848

Article  CAS  PubMed  Google Scholar 

Ma S, Charron J, Erikson RL (2003) Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 23:6936–6943

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kyuno D, Takasawa A, Kikuchi S, Takemasa I, Osanai M, Kojima T (2021) Role of tight junctions in the epithelial-to-mesenchymal transition of cancer cells. Biochim Biophys Acta BBA - Biomembr 1863:183503

Article  CAS  Google Scholar 

Campisi J, Andersen JK, Kapahi P, Melov S (2011) Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol 21:354–359

CAS  PubMed  PubMed Central  Google Scholar 

Wagner K-D, Wagner N (2022) The senescence markers p16INK4A, p14ARF/p19ARF, and p21 in organ development and homeostasis. Cells 11:1966

Article  CAS  PubMed